RocheBreast cancerGiredestrant demonstrates efficacy in early-stage breast cancerRoche has reported that its selective estrogen receptor degrader (SERD), giredestrant, has demonstrated significant clinical benefit in pivotal Phase III trials for adjuvant early-stage ER-positive, … more ➔
adobe.stock.photos - Yurii Kibalnik FinancingAvanzanite secures €32m Series A fundingDutch Avanzanite Biosciences NV has secured €32 m in a Series A financing round from MVM Partners to scale orphan drug commercialisation across Europe. more ➔
Biocom interrelations GmbHCell therapiesMillions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the GloomThe company Captain T Cell, spin-out from Max-Delbrück center in Berlin, now has a total of €20 million in funding and grants to push forward its novel cell therapies for solid tumours. New backers … more ➔
MitoRx Therapeutics LtdObesityMitoRx Therapeutics advances next-generation obesity therapyMitoRx Therapeutics Ltd has raised £5.5m in a seed financing to advance Myo‑004, a small molecule mitochondrial-targeted obesity therapy enabling fat loss while preserving lean muscle mass. more ➔
Sofinnova PartnersVenture CapitalSofinnova Partners surpasses target with €650m fund to back up early-stage biotechSofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but … more ➔
Medicxi FinancingMedicxi announces new €500m biotech investment fundVC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages. more ➔
chokniti - Adobe StockFinancingVirometix: US$15m for Synthetic VaccinesSwiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform. more ➔
Scripta TherapeuticsFinancingScripta Therapeutics raises $12m to flip the script on drug discoveryOxford-based techbio startup Scripta Therapeutics has emerged from stealth with a biology-first platform targeting the master regulators of disease. more ➔
adobe stock photos - JustlightHypertensionAZ’s baxdrostat mets endpoint in resistant hypertensionAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential. more ➔
stock.adobe.photos.com - gaviLicencing dealAstraZeneca bolsters obesity portfolio with muscle‑preserving buyAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market. more ➔
Roche
adobe.stock.photos - Yurii Kibalnik 
Biocom interrelations GmbH
MitoRx Therapeutics Ltd
Sofinnova Partners
Medicxi 
chokniti - Adobe Stock
Scripta Therapeutics
adobe stock photos - Justlight
stock.adobe.photos.com - gavi